Pfizer will report earnings on January 30. We expect the company to see a continued ramp up in its oncology drug sales, primarily Ibrance, which may inch closer to $1 billion in quarterly sales. We'll be closely watching Prevnar's performance, which beat street estimates in the previous quarter.
Pfizer will report earnings on January 30. We expect the company to see a continued ramp up in its oncology drug sales, primarily Ibrance, which may inch closer to $1 billion in quarterly sales. We'll be closely watching Prevnar's performance, which beat street estimates in the previous quarter.
Share this Article
Recommended